Amity University Noida to Introduce India’s First M.Sc. in Immunopharmacology Starting July 2026

For Real-World Disease Challenges

Diseases such as cancer, tuberculosis, and autoimmune disorders require more than expertise alone. They need a combined understanding of immune response and drug action.

This programme is built to address that need. It prepares students to study disease mechanisms while also exploring how targeted therapies can be developed and applied.

Research-Driven Learning from the Start

The structure of the programme moves beyond classroom learning. Students will work on real-world research problems, engaging with actual datasets and ongoing studies.

A key component is its collaboration with the All India Institute of Medical Sciences. This allows students to gain early exposure to clinical and translational research, bridging academic knowledge with practical application.

Faculty associated with the programme bring experience from international research environments, ensuring that students are trained in globally relevant scientific methods.

Career Pathways in Emerging Biomedical Fields

Immunopharmacology is central to areas such as immunotherapy, vaccine development, and precision medicine. As healthcare evolves, the demand for specialists continues to grow.

Graduates can explore opportunities in:

• Pharmaceutical and biotechnology research

• Clinical and translational science

• Vaccine and immunotherapy development

• Public health and regulatory research

Read Also: Amity University Placement

Strengthening Specialised Scientific Education

With this launch, Amity University Noida expands its focus on specialised, research-oriented programmes aligned with current healthcare needs. The M.Sc. in Immunopharmacology represents a focused academic step towards preparing professionals who can work across disciplines and contribute to solving complex medical challenges.

Disclaimer: This article has been published as a marketing collaboration between Careers360 and Amity University, Noida.